Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Trial Profile

Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Eltrombopag (Primary) ; Azacitidine; Decitabine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Oct 2013 New source identified and inegrated (M.D. Anderson Cancer Center: 2013-0225).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top